Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Travoprost. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR known ✓ | P43088 | 14/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.81 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.64 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Travoprost SCHEMBL10015920 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL11907120 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL2177084 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL10086843 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL15074545 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL2177092 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL20485616 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL20485617 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL20664855 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL1951740 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11563 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107180-A1 | IMPLANT INJECTOR DEVICE | OCULAR THERAPEUTIX, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-2308466-B2 | Aqueous pharmaceutical compositions containing borate-polyol complexes | NOVARTIS AG (CH) | 2026-05-20 | — | — | EP | claimed |
| WO-2026102187-A1 | ENGINEERED VIRUS-LIKE PARTICLES COMPRISING A BASE EDITOR FOR THE TREATMENT OF GLAUCOMA, AND APPLICATIONS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260131008-A1 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | CELLA THERAPEUTICS LLC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739302-A2 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | Cella Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4727651-A1 | METHOD OF ENHANCING THE SYSTEMIC HYPOGLYCEMIC EFFECT OF TOPICALLY APPLIED INSULIN WITH THE USE OF PROSTAGLANDIN ANALOGUES: A NOVEL FIXED COMBINATION EYE DROP FORMULATION OF INSULIN AND PROSTAGLANDIN ANALOGUE FOR THE LOWERING OF BLOOD GLUCOSE LEVEL | Gosiengfiao, David Harold (PH) | 2026-04-22 | — | — | EP | claimed |
| EP-3973954-B1 | PRESERVATIVE FREE PHARMACEUTICAL COMPOSITIONS FOR OPHTHALMIC ADMINISTRATION | NTC S R L (IT) | 2026-04-22 | — | — | EP | claimed |
| EP-4724839-A2 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | Mediprint Ophthalmics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| WO-2002005815-A1 | OPHTHALMIC FORMULATION OF A SELECTIVE CYCLOOXYGENASE-2 INHIBITORY DRUG | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-24 | — | — | WO | claimed |
| EP-1169061-A1 | COMBINATION THERAPY FOR TREATING GLAUCOMA | ALCON LABORATORIES, INC. (US) | 2002-01-09 | — | — | EP | claimed |
| WO-2001095913-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OF MYOPIA | SYNPHORA AB (SE) | 2001-12-20 | — | — | WO | claimed |
| US-20010047012-A1 | COMBINATION THERAPY FOR TREATING GLAUCOMA | ALCON RESEARCH, LTD. | 2001-11-29 | — | — | US | claimed |
| US-20010023258-A1 | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension | ALCON RESEARCH, LTD. | 2001-09-20 | — | — | US | claimed |
| EP-1115406-A2 | SUSTAINED RELEASE, AND COMFORTABLE OPHTHALMIC COMPOSITION AND METHOD FOR OCULAR THERAPY | ALCON LABORATORIES, INC. (US) | 2001-07-18 | — | — | EP | claimed |
| CN-1295483-A | Gelling ophthalmic composition containing xanthan gum | ALCON LAB INC (US) | 2001-05-16 | — | — | CN | claimed |
| CN-1272063-A | Prostaglandin product | ALCON LAB INC (US) | 2000-11-01 | — | — | CN | claimed |
| WO-2000054810-A1 | COMBINATION THERAPY FOR TREATING GLAUCOMA | ALCON LABORATORIES, INC (US) | 2000-09-21 | — | — | WO | claimed |
| WO-2000018316-A2 | SUSTAINED RELEASE, AND COMFORTABLE OPHTHALMIC COMPOSITION AND METHOD FOR OCULAR THERAPY | ALCON LABORATORIES, INC. (US) | 2000-04-06 | — | — | WO | claimed |